Comparative in vitro activity of oral antimicrobial agents against Enterobacteriaceae from patients with community-acquired urinary tract infections in three European countries

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
M KreskenH Seifert

Abstract

Enterobacteriaceae causing community-acquired urinary tract infections were examined in selected outpatient clinics and hospitals in Belgium, Germany and Spain using EUCAST breakpoints for susceptibility. A total of 1190 isolates were collected. Escherichia coli isolates were resistant to amoxicillin-clavulanic acid (28.1%), ciprofloxacin (23.4%) and trimethoprim-sulfamethoxazole (21.4%) compared with fosfomycin and nitrofurantoin (each, <1.5%). Ceftibuten (MIC50/90 0.25/0.5 mg/L) and ceftriaxone activity (MIC50/90 ≤0.25 mg/L) was comparable. Ceftibuten (MIC90 ≤0.25 mg/L) was also active against Proteus mirabilis and Klebsiella spp. Extended-spectrum β-lactamase phenotypes were 7.1% for E. coli, 5.6% for Klebsiella pneumoniae and 0.4% for P. mirabilis. Resistance was common among men and elderly women.

References

Feb 15, 2001·The Journal of Infectious Diseases·W E Stamm, S R Norrby
Nov 8, 2011·International Journal of Antimicrobial Agents·Gunnar Kahlmeter, Hanna Odén Poulsen
Jan 11, 2012·Antimicrobial Agents and Chemotherapy·Anna K StuckKathrin Mühlemann
May 4, 2012·The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases·Jaime L RochaJames R Johnson
Jul 3, 2013·Jornal brasileiro de nefrologia : ʹorgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia·Denise Swei LoAlfredo Elias Gilio
Oct 15, 2013·The Journal of Antimicrobial Chemotherapy·Lorena López-CereroJesús Rodríguez-Baño
Dec 3, 2013·Brazilian Journal of Microbiology : [publication of the Brazilian Society for Microbiology]·Afonso Gomes AbreuAzizedite Guedes Gonçalves
Sep 17, 2014·International Journal of Antimicrobial Agents·Michael KreskenUNKNOWN Working Party ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Chemotherapy
Oct 4, 2014·American Journal of Infection Control·Antonio SorlozanoJosé Gutiérrez-Fernández

❮ Previous
Next ❯

Citations

Aug 23, 2018·Transplant Infectious Disease : an Official Journal of the Transplantation Society·José M Arreola-GuerraJosé Sifuentes-Osornio
May 23, 2020·The Journal of Antimicrobial Chemotherapy·Adam G StewartDavid L Paterson
Aug 7, 2021·Infectious Diseases and Therapy·Balaji VeeraraghavanRani Diana Sahni

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.